Literature DB >> 15156186

Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11.

Katsuya Shigesada1, Bart van de Sluis, P Paul Liu.   

Abstract

Inv(16)(p13q22) is associated with acute myeloid leukemia subtype M4Eo that is characterized by the presence of myelomonocytic blasts and atypical eosinophils. This chromosomal rearrangement results in the fusion of CBFB and MYH11 genes. CBF beta normally interacts with RUNX1 to form a transcriptionally active nuclear complex. The MYH11 gene encodes the smooth muscle myosin heavy chain. The CBF beta-SMMHC fusion protein is capable of binding to RUNX1 and form dimers and multimers through its myosin tail. Previous results from transgenic mouse models show that Cbfb-MYH11 is able to inhibit dominantly Runx1 function in hematopoiesis, and is a key player in the pathogenesis of leukemia. In recent years, molecular and cellular biological studies have led to the proposal of several models to explain the function of CBF beta-SMMHC. In this review, we will first focus our attention on the molecular mechanisms proposed in the recent publications. We will next examine recent gene expression profiling studies on inv(16) leukemia cells. Finally, we will describe a recent study from one of our labs on the identification of cooperating genes for leukemogenesis with CBFB-MYH11.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15156186     DOI: 10.1038/sj.onc.1207748

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  25 in total

1.  Sequence analysis of mutations and translocations across breast cancer subtypes.

Authors:  Shantanu Banerji; Kristian Cibulskis; Claudia Rangel-Escareno; Kristin K Brown; Scott L Carter; Abbie M Frederick; Michael S Lawrence; Andrey Y Sivachenko; Carrie Sougnez; Lihua Zou; Maria L Cortes; Juan C Fernandez-Lopez; Shouyong Peng; Kristin G Ardlie; Daniel Auclair; Veronica Bautista-Piña; Fujiko Duke; Joshua Francis; Joonil Jung; Antonio Maffuz-Aziz; Robert C Onofrio; Melissa Parkin; Nam H Pho; Valeria Quintanar-Jurado; Alex H Ramos; Rosa Rebollar-Vega; Sergio Rodriguez-Cuevas; Sandra L Romero-Cordoba; Steven E Schumacher; Nicolas Stransky; Kristin M Thompson; Laura Uribe-Figueroa; Jose Baselga; Rameen Beroukhim; Kornelia Polyak; Dennis C Sgroi; Andrea L Richardson; Gerardo Jimenez-Sanchez; Eric S Lander; Stacey B Gabriel; Levi A Garraway; Todd R Golub; Jorge Melendez-Zajgla; Alex Toker; Gad Getz; Alfredo Hidalgo-Miranda; Matthew Meyerson
Journal:  Nature       Date:  2012-06-20       Impact factor: 49.962

Review 2.  Whole genome scanning as a cytogenetic tool in hematologic malignancies.

Authors:  Jaroslaw P Maciejewski; Ghulam J Mufti
Journal:  Blood       Date:  2008-05-27       Impact factor: 22.113

3.  inv(16) and NPM1mut AMLs engraft human cytokine knock-in mice.

Authors:  Jana M Ellegast; Philipp J Rauch; Larisa V Kovtonyuk; Rouven Müller; Ulrich Wagner; Yasuyuki Saito; Nicole Wildner-Verhey van Wijk; Christine Fritz; Anahita Rafiei; Veronika Lysenko; Ewa Dudkiewicz; Alexandre P Theocharides; Davide Soldini; Jeroen S Goede; Richard A Flavell; Markus G Manz
Journal:  Blood       Date:  2016-08-31       Impact factor: 22.113

4.  CBFB-MYH11/RUNX1 together with a compendium of hematopoietic regulators, chromatin modifiers and basal transcription factors occupies self-renewal genes in inv(16) acute myeloid leukemia.

Authors:  A Mandoli; A A Singh; P W T C Jansen; A T J Wierenga; H Riahi; G Franci; K Prange; S Saeed; E Vellenga; M Vermeulen; H G Stunnenberg; J H A Martens
Journal:  Leukemia       Date:  2013-09-04       Impact factor: 11.528

5.  CBFB-MYH11 hinders early T-cell development and induces massive cell death in the thymus.

Authors:  Ling Zhao; Jennifer L Cannons; Stacie Anderson; Martha Kirby; Liping Xu; Lucio H Castilla; Pamela L Schwartzberg; Rémy Bosselut; P Paul Liu
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  Frequent genomic abnormalities in acute myeloid leukemia/myelodysplastic syndrome with normal karyotype.

Authors:  Tadayuki Akagi; Seishi Ogawa; Martin Dugas; Norihiko Kawamata; Go Yamamoto; Yasuhito Nannya; Masashi Sanada; Carl W Miller; Amanda Yung; Susanne Schnittger; Torsten Haferlach; Claudia Haferlach; H Phillip Koeffler
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

7.  PEBP2-beta/CBF-beta-dependent phosphorylation of RUNX1 and p300 by HIPK2: implications for leukemogenesis.

Authors:  Hee-Jun Wee; Dominic Chih-Cheng Voon; Suk-Chul Bae; Yoshiaki Ito
Journal:  Blood       Date:  2008-08-11       Impact factor: 22.113

8.  Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBFβ interaction.

Authors:  Lea Cunningham; Steven Finckbeiner; R Katherine Hyde; Noel Southall; Juan Marugan; Venkat R K Yedavalli; Seameen Jean Dehdashti; William C Reinhold; Lemlem Alemu; Ling Zhao; Jing-Ruey Joanna Yeh; Raman Sood; Yves Pommier; Christopher P Austin; Kuan-Teh Jeang; Wei Zheng; Paul Liu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-08-21       Impact factor: 11.205

9.  FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia.

Authors:  Hyung-Gyoon Kim; Kyoko Kojima; C Scott Swindle; Claudiu V Cotta; Yongliang Huo; Vishnu Reddy; Christopher A Klug
Journal:  Blood       Date:  2007-10-29       Impact factor: 22.113

10.  PU.1 activation relieves GATA-1-mediated repression of Cebpa and Cbfb during leukemia differentiation.

Authors:  Pavel Burda; Nikola Curik; Juraj Kokavec; Petra Basova; Dana Mikulenkova; Arthur I Skoultchi; Jiri Zavadil; Tomas Stopka
Journal:  Mol Cancer Res       Date:  2009-10-13       Impact factor: 5.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.